**(See the editorial commentary by Branche and Falsey, on pages 923--5.)**

Acute respiratory tract infections are common causes of infection-related deaths worldwide. Differentiating between bacterial and viral infections can be clinically challenging, frequently leading to empirical antibacterial therapy, which, in turn, contributes to the burden of antimicrobial resistance \[[@CIT0001]\].

In recent antimicrobial stewardship implementation guidelines, rapid testing for broad panels of respiratory viruses was advocated as an important intervention to reduce the use of inappropriate antibiotics for respiratory tract infections (weak recommendation/poor quality evidence) \[[@CIT0004]\]. Nucleic acid amplification--based tests are now the gold standard for laboratory confirmation of respiratory viruses \[[@CIT0005], [@CIT0006]\]; however, they can be costly, especially when targeting a broad array of viruses. In the absence of solid outcome studies specifically assessing their impact on antimicrobial use and hospital resource utilization, institutions face difficult decisions on the choice of tests and the patients most likely to benefit from testing \[[@CIT0007]\]. Studies conducted among pediatric populations have shown that rapid viral testing generally contributes to reducing antibiotic use \[[@CIT0008]\], but those among adult patients have yielded conflicting results. Small reductions in antibiotic use, shorter durations of hospitalization, and lower overall costs were noted in some studies when test results were communicated to physicians rapidly \[[@CIT0011]\]. However, these were limited by small sample sizes, by comparisons only to historical controls, or by the fact that they only included outpatients---making it difficult to extrapolate their results to acute care hospital settings.

We introduced a laboratory-developed, real-time polymerase chain reaction--based 12--respiratory virus panel (RVP) in our institution in 2009. The RVP had an overall positivity rate (calculated using data from all seasons and for all patients) of around 30% and turnaround times of 6--24 hours and was quickly adopted by clinicians as a useful tool for analyzing patients presenting with acute respiratory syndromes. The objective of this study was to prospectively evaluate whether rapid viral test results lead to changes in antimicrobial prescriptions among adults hospitalized with respiratory tract infections and whether these results can help predict important clinical outcomes. Data from this study will better inform the role of respiratory virus testing within antibiotic stewardship programs.

METHODS {#s1}
=======

Study Setting and Ethical Approval {#s2}
----------------------------------

The McGill University Health Centre (MUHC) is an 850-bed tertiary care center in downtown Montreal, Canada, with 2 hospital campuses for adult patients. Patients presenting with respiratory symptoms are tested by RVP at the discretion of the treating teams. Staff are reminded every winter season (via memos and posted notices) of the importance of respiratory virus testing, particularly for patients requiring admission for which appropriate infection control measures need to be implemented.

For this study, we performed secondary analyses of data collected in the context of surveillance for serious influenza illness and vaccine effectiveness, sponsored by the Serious Outcomes Surveillance Network of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network \[[@CIT0015]\], and received ethics approval by the institutional review board of the MUHC.

Data Collection {#s3}
---------------

We prospectively identified potential study participants from the laboratory logs of RVP testing during 3 consecutive winters (November--April 2012--2013, 2013--2014, and 2014--2015). After cross-referencing data to the hospital information system, we screened RVP-tested patients who were hospitalized (for ≥24 hours), for potential enrollment. Eligibility criteria included acute respiratory tract infection (ie, pneumonia and influenza-like illness), exacerbation of chronic obstructive pulmonary disease (COPD) or asthma, unexplained sepsis, and influenza-like symptoms (eg, fever, dyspnea, cough, sore throat, and myalgia). Subjects were excluded if they were tested for respiratory viruses \>7 days after onset of symptoms (since detection of viral nucleic acids in these cases might not be correlated with active infection), if infection was considered acquired in hospital, or if their reason for admission was clearly unrelated to a respiratory tract infection.

Trained clinical research monitors extracted the following data from medical records on all enrolled patients: age, sex, comorbidities, frailty scores for patients aged \>65 years (scores were defined on a scale of 1 to 9, with 1 denoting very fit and 9 denoting terminally ill \[[@CIT0016]\]), radiographic suspicion (by any physician) of pneumonia at the time of admission, complications (eg, thromboembolism and *Clostridium difficile* infection) during hospitalization, and hospitalization details, including intensive care unit (ICU) admission, antibiotic and antiviral prescription data, duration of hospitalization, and death. The study monitors sought informed consent to interview patients for detailed vaccine and healthcare utilization information in the context of the vaccine effectiveness study. Subjects who did not provide consent were excluded from the vaccine effectiveness analysis but not from the current study because only deidentified clinical data obtained from chart reviews were analyzed.

The principal investigator (M. S.) reviewed all data and an external auditor monitored data quality yearly.

RVP {#s4}
---

Nasopharyngeal swab specimens were collected from patients by treating teams upon the orders of the physician, placed in a universal transport medium, and sent to the laboratory the same day. The testing panel targeted influenza A and B viruses, respiratory syncytial virus (RSV) A and B, rhinovirus/enterovirus, parainfluenza virus 1--3, adenovirus, human metapneumovirus, and coronavirus OC43 and 229E. The RVP assay developed at the MUHC was validated as having lower limits of detection for all viruses, compared with those for direct fluorescent antibody and culture \[[@CIT0014]\].

RVP testing was done 3--4 times per day on weekdays (early morning, afternoon, evening, and overnight runs) and 2--3 times per day on weekends, depending on the volume of specimens. The minimal analytical testing time was 4.5 hours, and turnaround times ranged from 6 to 24 hours (median turnaround time from specimen collection to final verification was 8 hours 51 minutes for the hospital in which the laboratory is situated and 15 hours 4 minutes for the second hospital, situated 2.5-km away). Results of RVP were faxed to the ward and were also immediately available electronically on the hospital laboratory information system; additionally, to avoid delays in management, treating teams were notified by telephone of all positive test results labeled as "preliminary," even before the final report was issued.

Outcome Measures {#s5}
----------------

We analyzed antibiotics prescribed for presumed respiratory tract infection or unexplained sepsis (ceftriaxone, doxycycline, azithromycin, piperacillin-tazobactam, imipenem, meropenem, intravenous vancomycin, moxifloxacin, and levofloxacin) as per our institution's guidelines for empirical therapy and did not include antibiotics prescribed for other infections (eg, cefazolin and oral vancomycin). The only antiviral used in our institution for treatment of influenza was oseltamivir.

Our main objective was to evaluate whether rapid availability of RVP results had an impact on antimicrobial use in hospital; specifically, we evaluated whether knowledge of the RVP result led to a change in antimicrobial prescription. To define a change in treatment, we first distinguished between patients who were treated before testing and those who were not. Because it was not possible to determine precisely when the treating physician became aware of the test result and on the basis of a turnaround time of \<24 hours, we made 2 assumptions. First, antimicrobials prescribed on or before the date of test collection (day 0) were started before testing. Among these, change was measured in terms of discontinuation of treatment with the antimicrobial on day 1 or 2 after testing (eg, discontinuation of antibiotics if the RVP detected a virus). Second, among patients who were not treated before testing, change was measured in terms of commencing antimicrobial treatment on day 1 or 2 after testing (eg, commencing antiviral if the RVP detected influenza virus). We hypothesized that a positive test result for influenza virus would be associated with the continuation or commencement of antiviral treatment and that a detection of any virus by RVP would result in a greater likelihood of discontinuation of antibiotics, particularly in patients for whom there was no radiographic suspicion of pneumonia.

Statistical Analysis {#s6}
--------------------

We classified patients according to their RVP findings: influenza virus positive, positive for viruses other than influenza virus (hereafter, "other virus positive"), and virus negative. Patients who tested positive for influenza virus and another virus were analyzed in the influenza virus--positive group. We compared clinical characteristics of the patients by calculating differences in means (for continuous characteristics) or proportions (for categorical characteristics) with associated 95% confidence intervals (CIs). For differences in proportions, we calculated a confidence interval by using the Wilson method.

To study the impact of the RVP finding on the outcome measures, we stratified patients by whether they began treatment before testing and by (suspected) pneumonia status. Among patients who began treatment before testing, we calculated the percentage of patients who discontinued antimicrobial treatment for each of the 3 categories defined by the RVP result. Likewise, for each of the 3 categories of findings yielded by the RVP, we calculated the percentage of patients who commenced antimicrobial treatment after testing. Results for antiviral and antibiotic treatments were analyzed separately.

To adjust for confounding variables, we fit Cox proportional hazard models of the main outcome measures that included RVP findings, age, Charlson index (a comorbidity index based on the number of preexisting chronic conditions present on admission and validated to predict mortality in longitudinal studies \[[@CIT0017]\]), and suspicion of pneumonia as independent variables. Patients whose antimicrobial treatment was discontinued because of death or hospital discharge were treated as censored. Patients who began treatment before testing and had received antivirals for 3 days on the date a specimen was collected for analysis by the RVP (therefore would have completed 5 days of treatment within 2 days of testing) were dropped from these models.

All analyses were performed using SAS, version 9.3 (SAS Institute).

RESULTS {#s7}
=======

Study Population {#s8}
----------------

A total of 1093 adult patients (tested by RVP during the study period) were screened for enrollment; of these, 800 were hospitalized and met eligibility criteria and, therefore, were included for detailed analysis ([Figure 1](#F1){ref-type="fig"}).

![Flowchart describing selection of patients for analysis. ^a^Treatment with antivirals (oseltamivir) and/or antibiotics for a respiratory tract infection or unexplained sepsis. ^b^Patients who initiated treatment prior to testing and were receiving treatment on the day of specimen collection for respiratory virus panel (RVP) testing. ^c^Patients who were treated after RVP findings were available (all started treatment ≥1 day after specimen collection for RVP testing), patients who were not treated, patients who started and ended treatment prior to testing, and patients who received an antibiotic for a nonrespiratory illness.](jix28801){#F1}

Over the 3 winters, 425 study patients (53%) had influenza virus--positive results (342 tested positive for influenza A virus, and 83 tested positive for influenza B virus), and 81 (10%) had other virus--positive results. The viruses other than influenza virus that were detected most frequently were adenovirus and RSV (3.6% and 3%, respectively) ([Table 1](#T1){ref-type="table"}). Two or more viruses were detected in 25 patients (3%).

###### 

Respiratory Virus Panel Findings

  **Virus**                  **Positive Test Results, Patients, No. (%**)
  -------------------------- ----------------------------------------------
  Influenza A and B virus    425 (53)
  RSV A and B                24 (3)
  Parainfluenza virus 1--3   4 (0.5)
  Rhinovirus/enterovirus     6 (0.8)
  Adenovirus                 29 (3.6)
  CoV OC43 and 229E          11 (1.4)
  Human metapneumovirus      13 (1.6)

Abbreviations: CoV, coronavirus; RSV, respiratory syncytial virus.

The 3 groups of patients (influenza virus positive, other virus positive, and virus negative) were comparable in terms of sex distribution, age, and Charlson index ([Table 2](#T2){ref-type="table"}). Influenza virus--positive patients were frailer than other virus--positive patients (difference, 1.4 \[95% CI, .8--1.9\]) and virus-negative patients (difference, 1 \[95% CI, .6--1.3\]), but their duration of hospitalization was lower than for the other 2 groups (difference, --2.4 \[95% CI, --4.71 to --.03\]; Supplementary Table 2).

###### 

Demographic and Clinical Characteristics of Study Population, by Respiratory Virus Panel (RVP) Results

  --------------------------------------------------------------------------------------------------------------------------------------
  Variable                              Overall\          Influenza Virus Positive (n = 425)   Other Virus Positive\   Virus Negative\
                                        (n = 800)                                              (n = 69)                (n = 306)
  ------------------------------------- ----------------- ------------------------------------ ----------------------- -----------------
  Age, y                                                                                                               

  Mean ± SD                             70.1 **±** 18.0   71.2 **±** 18.2                      67.6 **±** 15.5         69.2 **±** 18.3

  Median                                73.0              76.0                                 67.0                    72.0

  Charlson index                                                                                                       

  Mean ± SD                             2.9 **±** 2.5     2.7 **±** 2.4                        3.0 **±** 2.5           3.2 **±** 2.7

  Median                                2.0               2.0                                  2.0                     2.0

  Frailty scale                                                                                                        

  Mean ± SD                             5.15 **±** 1.9    5.6 **±** 2.0                        4.2 **±** 1.6           4.6 **±** 1.8

  Median                                5.0               6.0                                  4.0                     5.0

  Length of stay, d                                                                                                    

  Mean ± SD                             13.4 **±** 16.4   12.4 **±** 15.6                      13.8 **±** 21.4         14.8 **±** 16.1

  Median                                8.0               7.0                                  7.0                     10.0

  Female sex                            427 (53.4)        225 (52.9)                           36 (52.2)               166 (54.3)

  Admitted to ICU                       95 (11.9)         53 (12.5)                            9 (13.0)                33 (10.8)

  Received mechanical ventilation       66 (8.3)          38 (8.9)                             4 (5.8)                 24 (7.8)

  Received BiPAP therapy                54 (6.8)          34 (8.0)                             7 (10.1)                13 (4.3)

  Received supplemental O~2~ therapy    480 (60.0)        243 (57.2)                           51 (73.9)               186 (60.8)

  Radiographic suspicion of pneumonia                                                                                  

  Yes                                   322 (40.3)        141 (33.2)                           34 (49.3)               147 (48.4)

  No                                    459 (57.4)        270 (63.5)                           33 (47.8)               156 (51.3)

  Unknown                               19 (2.4)          14 (3.3)                             2 (2.9)                 3 (1.0)

  Death                                                                                                                

  Overall                               64 (8.0)          39 (9.2)                             3 (4.4)                 22 (7.2)

  Unrelated to infection                22 (34.4)         5 (12.8)                             0 (0.0)                 17 (77.3)

  Directly related to infection         25 (39.1)         23 (59.0)                            1 (33.3)                1 (4.6)

  Indirectly related to infection       16 (25.0)         11 (28.2)                            1 (33.3)                4 (18.2)

  Missing cause                         1 (0.2)           0 (0.0)                              1 (33.3)                0

  Complication                                                                                                         

  Yes                                   324 (40.5)        172 (40.5)                           22 (31.9)               130 (42.5)

  No                                    448 (56.0)        235 (55.3)                           44 (63.8)               169 (55.2)

  Unknown                               28 (3.5)          18 (4.2)                             3 (4.4)                 7 (2.3)
  --------------------------------------------------------------------------------------------------------------------------------------

Data are no. (%) of patients, unless otherwise indicated.

Abbreviations: BiPAP, bilevel positive airway pressure; ICU, intensive care unit.

A total of 322 patients (40%) had radiographic suspicion of pneumonia at admission. A suspicion of pneumonia was least common among influenza virus--positive patients, compared with other virus--positive patients (difference, 16.1 \[95% CI, 4--28\]) and virus-negative patients (difference, 15.2 \[95% CI, 8--22\]). The proportion of patients admitted to the ICU was not significantly different between the 3 groups; however, the need for supplemental oxygen was more common in the other virus--positive group, compared with the influenza virus--positive group (difference, 16.7 \[95% CI, 4--27\]) and the virus-negative group (difference, 13.1 \[95% CI, 1--24\]). Of the 3 deaths in this group, 1 patient tested positive for RSV, and 2 tested positive for rhinovirus.

Patients Treated Before Versus After Testing {#s9}
--------------------------------------------

A total of 464 patients (58%) initiated antibiotics and/or antivirals before testing ([Table 3](#T3){ref-type="table"}). A suspicion of pneumonia was more common in this group, compared with those treated after testing (difference, 25 \[95% CI, 19--32\]; Supplementary Table 3), but clinical outcomes (death, ICU admission, and complications) were similar in frequency.

###### 

Characteristics of Empirically Treated Versus Non--Empirically Treated Patients

  Variable                              Treated Empirically (n = 464)   Not Treated Empirically (n = 336)
  ------------------------------------- ------------------------------- -----------------------------------
  Age, y                                                                
  Mean ± SD                             71.1 **±** 17.1                 68.7 **±** 19.3
  Median                                75.0                            72.0
  Charlson index                                                        
  Mean ± SD                             2.8 **±** 2.4                   3.1 **±** 2.7
  Median                                2.0                             2.0
  Frailty scale                                                         
  Mean ± SD                             5.1 **±** 2.0                   5.1 **±** 1.7
  Median                                5.0                             5.0
  Length of stay, d                                                     
  Mean ± SD                             12.7 **±** 15.0                 14.3 **±** 18.2
  Median                                8.0                             8.0
  Female sex                            246 (53.0)                      181 (53.9)
  Admitted to ICU                       63 (13.6)                       32 (9.5)
  Received mechanical ventilation       44 (9.5)                        22 (6.6)
  Received supplemental O~2~ therapy    309 (66.6)                      171 (50.9)
  Radiographic suspicion of pneumonia                                   
  Yes                                   236 (50.9)                      86 (25.6)
  No                                    222 (47.8)                      237 (70.5)
  Unknown or missing data               6 (1.3)                         13 (3.9)
  Death                                                                 
  Unrelated to infection                40 (8.6)                        24 (7.1)
  Directly related to infection         8 (20.0)                        14 (58.3)
  Indirectly related to infection       21 (52.5)                       4 (16.7)
  Missing cause                         10 (25.0)                       6 (25.0)
  Overall                               1 (0.2)                         0 (0.0)
  Complication                                                          
  Yes                                   195 (42.0)                      129 (38.4)
  No                                    253 (54.5)                      195 (58.0)
  Unknown                               16 (3.5)                        12 (3.6)
  RVP finding                                                           
  Influenza virus positive              266 (57.3)                      159 (47.3)
  Other virus positive                  33 (7.1)                        36 (10.7)
  Virus negative                        165 (35.6)                      141 (42.0)

Data are no. (%) of patients, unless otherwise indicated.

Abbreviations: ICU, intensive care unit; RVP, respiratory virus panel.

Change in Antimicrobials After Availability of RVP Findings {#s10}
-----------------------------------------------------------

Among influenza positive patients without radiographic suspicion of pneumonia, oseltamivir was continued in 79% ([Table 4](#T4){ref-type="table"}). After censoring influenza virus--positive patients who died, were discharged, or had completed 5 days of oseltamivir within 2 days of testing, oseltamivir was discontinued in 15 (6 with and 9 without a suspicion of pneumonia); renal failure was cited as the reason for discontinuation in 7 cases. Univariate regression analysis confirmed that discontinuing oseltamivir after availability of RVP findings was significantly less likely in the influenza virus--positive group as compared to the influenza virus--negative group (odds ratio \[OR\], 0.12 \[95% CI, .06--.22\]; [Table 6](#T6){ref-type="table"}). Among patients who initiated antibiotics before testing and had laboratory confirmation of influenza virus infection, antibiotics were discontinued in 37% of those with and 47% of those without a suspicion of pneumonia ([Table 4](#T4){ref-type="table"}). Antibiotic discontinuation was significant in the univariate analysis (OR, 1.59 \[95% CI, 1.03--2.44\]; [Table 6](#T6){ref-type="table"}). After laboratory confirmation of another virus, antibiotics were discontinued in 20% of patients with and 57% of those without a suspicion of pneumonia.

###### 

Change in Management of Antivirals and Antibiotics After Respiratory Virus Panel (RVP) Testing Among Patients Treated Empirically (Before Testing), by RVP Result

  -------------------------------------------------------------------------------------------
  Treatment, Pneumonia Suspicion   Influenza Virus\   Other Virus Positive   Virus Negative
                                   Positive                                  
  -------------------------------- ------------------ ---------------------- ----------------
  Antivirals                                                                 

  Suspicion                                                                  

  Patients                         47^a^              4                      18

  Antiviral continued^b^           37 (79)            0 (0)                  1 (6)

  No suspicion                                                               

  Patients                         100^a^             5                      12

  Antiviral continued^c^           81 (81)            1 (20)                 6 (50)

  Antibiotics                                                                

  Suspicion                                                                  

  Patients^d^                      57                 15                     90

  Antibiotic continued^e^          35 (61)            12 (80)                63 (70)

  No suspicion                                                               

  Patients^d^                      53                 7                      42

  Antibiotic continued^f^          21 (40)            1 (14)                 26 (62)
  -------------------------------------------------------------------------------------------

Data are no. or no. (%) of patients.

^a^Excludes 3 patients because of unknown pneumonia status.

^b^Among patients for whom antivirals were discontinued, 5 (4 influenza virus positive and 1 virus negative) either died, were discharged from hospital, or had completed 5 days of oseltamivir therapy within 2 days of testing.

^c^Among patients for whom antivirals were discontinued, 10 (all influenza virus positive) either died, were discharged from hospital, or had completed 5 days of oseltamivir therapy within 2 days of testing.

^d^One influenza virus--positive patient and 1 virus-negative patient are excluded because of unknown pneumonia status.

^e^Among patients for whom antibiotics were discontinued, 6 (1 influenza virus positive and 5 virus negative) either died or were discharged from hospital within 2 days of testing.

^f^Among patients for whom antibiotics were discontinued, 10 (7 influenza virus positive, 2 other virus positive, and 1 virus negative) either died or were discharged from hospital within 2 days of testing.

If treatment was not started before testing, an influenza virus--positive result led to starting oseltamivir in 24% of patients with and 44% of those without a suspicion of pneumonia. Among patients with a suspicion of pneumonia, antibiotics were prescribed to 22% in the influenza virus--positive group, 38% in the other virus--positive group, and 23% in the virus-negative group ([Table 5](#T5){ref-type="table"}).

###### 

Initiation of Treatment for a Respiratory Illness or Unknown Diagnosis ≤2 Days After Respiratory Virus Panel (RVP) Testing Among Patients Who Were Not Treated Empirically, by RVP Finding

  Pneumonia Suspicion, Treatment                Influenza Virus Positive   Other virus positive   Virus Negative
  --------------------------------------------- -------------------------- ---------------------- ----------------
  Suspicion                                                                                       
  Patients                                      35                         15                     36
  Antiviral started ≤48 h after testing^a^      10 (24)                    0 (0)                  4 (9)
  Antibiotic started ≤48 h after testing^b,c^   9 (22)                     6 (38)                 10^i^ (23)
  No suspicion                                                                                    
  Patients                                      115                        20                     102
  Antiviral started ≤48 h after testing^a^      54 (44)                    1 (5)                  4 (4)
  Antibiotic started ≤48 h after testing^c^     18 (15)                    3 (14)                 11(10)

Data are no. or no. (%) of patients. Denominators exclude 13 patients because of missing pneumonia status.

^a^Excludes 6 patients because of unknown pneumonia status.

^b^Excludes 2 patients because of unknown pneumonia status.

^c^Data are for patients receiving antibiotics for a respiratory-related illness or an unclear diagnosis only.

Impact of RVP Findings on Clinical Management {#s11}
---------------------------------------------

Results of multivariate Cox proportional hazards models appear in [Table 6](#T6){ref-type="table"}. An influenza virus--positive test result was very significantly correlated with oseltamivir use: influenza virus--positive patients who were not receiving antivirals before testing were 9 times as likely (OR, 9.38 \[95% CI, 4.48--19.61\]) to initiate oseltamivir after laboratory confirmation of influenza virus infection, compared with virus-negative patients. Similarly, among patients who were receiving antivirals before testing, influenza virus--positive patients were 0.1 times as likely to have their antivirals discontinued (OR, 0.1 (95% CI, .05--.20\]), compared with virus-negative patients.

###### 

Findings of Univariate and Multivariate Logistic Regression

  Variable                              Empirically Treated (Before Testing)   Not Empirically Treated                        
  ------------------------------------- -------------------------------------- ------------------------- -------------------- -------------------
  Univariate                                                                                                                  
  Age                                   1.01 (.99--1.02)                       1.02 (1.00--1.03)         1.00 (.99--1.01)     1.00 (.99--1.01)
  Charlson index                        1.07 (.95--1.19)                       1.00 (.92--1.09)          0.96 (.88--1.05)     1.00 (.91--1.10)
  Radiographic suspicion of pneumonia   2.61 (1.44--4.72)                      0.61 (.41--.93)           0.64 (.36--1.15)     2.20 (1.30--3.72)
  Influenza virus test result                                                                                                 
  Negative                              Reference                              Reference                 Reference            Reference
  Positive                              0.12 (.06--.22)                        1.59 (1.03--2.44)         8.38 (4.03--17.44)   1.19 (.67--2.09)
  Other virus positive                  1.46 (.65--3.31)                       1.18 (.53--2.65)          0.99 (.21--4.66)     1.92 (.90--4.07)
  Multivariate                                                                                                                
  Age                                   1.00 (.98--1.02)                       1.02 (1.00--1.03)         1.00 (.98--1.01)     1.00 (.98--1.01)
  Charlson index                        1.05 (.93--1.18)                       1.01 (.92--1.10)          0.98 (.90--1.07)     0.98 (.89--1.09)
  Radiographic suspicion of pneumonia   1.99 (1.05--3.75)                      0.59 (.39--.90)           0.68 (.38--1.22)     2.30 (1.35--3.90)
  RVP finding                                                                                                                 
  Virus negative                        Reference                              Reference                 Reference            Reference
  Influenza virus positive              0.10 (.05--.20)                        1.38 (.89--2.16)          9.38 (4.48--19.61)   1.21 (.68--2.15)
  Other virus positive                  1.95 (.82--4.65)                       1.33 (.59--2.98)          0.52 (.07--4.18)     1.60 (.73--3.51)

Data are odds ratios (95% confidence intervals).

Abbreviation: RVP, respiratory virus panel.

We noted a trend to discontinue antibiotics after an influenza virus--positive test result in the univariate analysis, but this was no longer significant after adjustment for potential confounders (OR, 1.38 \[95% CI, .89--2.16\]). Only a radiographic suspicion of pneumonia on admission was correlated with continuation of antibiotics treatment among patients treated before the availability of test results or with commencement of antibiotics among those treated after the availability of test results.

DISCUSSION {#s12}
==========

Our goal was to assess whether rapid testing for a broad panel of viruses would be a useful tool for antimicrobial stewardship efforts, particularly in the early management of adults requiring hospitalization, and whether viral detection leads to different clinical outcomes. We hypothesized that knowledge of influenza virus positivity would lead to institution of appropriate antivirals and de-escalation of antibiotics and that positivity for other viruses would lead to cessation of oseltamivir and antibiotics.

Our patient population consisted of moderately vulnerable or frail, mostly elderly patients already at significant risk of death within 1 year (based on Charlson indexes corresponded to predicted 1-year mortality rates of 26%--52% \[[@CIT0017]\]), the majority of whom started antimicrobial therapy for presumed respiratory tract infection upon presentation, before RVP results were available. Over 3 consecutive winters, influenza virus was detected in 53% of study patients; this frequency was significantly higher than the overall rate of influenza virus detection in the community. Based on results from our laboratory, influenza virus was detected in 9%--16% and other respiratory viruses in 21%--39% of all nasopharyngeal specimens (including those from children and ambulatory patients) during the study period, suggesting that influenza virus was a major cause of admission for respiratory tract infections among adults in our institution. One study from a setting similar to ours, in Quebec, Canada, reported higher relative contributions of viruses other than influenza virus among their patients, but these contributions were variable from year to year, accounting for 25% of infections one year and only 16% the next \[[@CIT0018]\]. In our study, nearly half of other virus--positive patients had radiographic suspicion of lower respiratory tract infections, and the majority required supplemental oxygen therapy, suggesting that these viruses were likely implicated in lower respiratory tract infections or COPD/asthma exacerbations. However, positivity for viruses other than influenza virus did not appear to be an important determinant of significant clinical outcomes, such as duration of hospitalization.

Observational data suggest that early initiation of oseltamivir is associated with improved overall outcomes and fewer influenza-related complications in hospitalized patients \[[@CIT0019]\]. Our data confirm that clinicians use rapidly available results of influenza virus testing to guide appropriate appropriate antiviral therapy. If the RVP detected influenza virus, physicians were 10 times as likely to continue oseltamivir that was started empirically or 9 times as likely to start oseltamivir de novo than if the RVP had negative results. However, among patients who did not start therapy before testing, fewer than half were prescribed oseltamivir after confirmation of influenza virus, presumably because physicians deemed the delay was too long for the patients' benefit. The association between RVP positivity and de-escalation of antibiotics was of smaller magnitude: patients started on antibiotics before testing and were subsequently found to test positive for influenza virus were roughly 1.4 times as likely to have their antibiotics discontinued as compared to those who tested negative, but the association was not statistically significant after adjustment for potential confounders, such as age and comorbidity. The variable most significantly correlated with continuation of antibiotics started before testing was radiographic suspicion of pneumonia. Despite the well-established fact that chest radiography findings do not reliably differentiate between bacterial and viral lower respiratory tract infections, nor even between infectious and noninfectious illnesses, clinicians appear to be influenced more by radiographic findings than by viral test results when making antibiotic management decisions, probably because of concerns about bacterial coinfection. This was not only true for patients who started empirical therapy and presumably had more-severe illness at presentation---patients who were not treated before testing and were subsequently found to have a positive RVP result were just as likely as those testing negative for all viruses to start antibiotics within the first 2 days.

In agreement with our data, 2 retrospective analyses from Canada showed that influenza virus positivity led to increased use of antivirals, but test results did not correlate with overall antibiotic use \[[@CIT0014], [@CIT0022]\]. Also, 2 European studies found no association between test results and antibiotic use or overall costs \[[@CIT0023], [@CIT0024]\].

These findings have important implications for antimicrobial stewardship programs in adult acute care hospitals: merely providing access to rapid multiplex testing may not be sufficient to reduce antibiotic use, even during winter, when influenza virus and other viral pathogens are frequent. The ability to interpret positive results in the context of clinical illness and the legitimate concerns of bacterial coinfections need to be addressed. Some have proposed the use of procalcitonin-guided algorithms to predict bacterial infection \[[@CIT0025]\], but this approach has yet to gain wide acceptance. A recent randomized controlled trial evaluating an algorithm combining procalcitonin measurement with viral testing noted a trend toward decreased duration of antibiotics in the subgroup with the lowest risk for bacterial infection, suggesting that physicians can respond to a combination of viral and biomarker data. However, that study excluded patients with radiographic suspicion of pneumonia, making it difficult to extrapolate the conclusions to other populations \[[@CIT0028]\].

Our data also question the pertinence of panels targeting a broad array of respiratory viruses for hospitalized patients. While the ability to detect a wide range of viruses might be critical for immunocompromised patients, testing only for viruses commonly linked to lower respiratory tract infections (ie, influenza virus, RSV, and possibly adenovirus and metapneumovirus) might be more cost-effective and sufficient for the purposes of antimicrobial stewardship. Viruses typically associated with upper tract infections (eg, rhinovirus/enterovirus and parainfluenza virus) are indeed common in children and in ambulatory adults, and their detection is potentially useful for determining a viral etiology for asthma/COPD exacerbations. However, they are less frequently implicated in hospitalized adults, and physicians have legitimate difficulties interpreting the significance of their detection in clinical specimens.

Our study has a few limitations. First, we used a prospective but nonrandomized design, as this was our only option for comparing the impact of a change in management following availability of test results to a situation where no test was available. Such designs have been shown to be valid for diagnostic test evaluation; we used carefully defined selection criteria and adjusted for confounding variables to limit biases. Second, we restricted our analysis to antimicrobial use in the first 2 days after testing, because our objective was to assess immediate changes attributable to test result. It is possible that antimicrobial use over the course of hospitalization would have been lower among patients with positive RVP findings, but it is equally or more likely that antibiotics would have been given for additional indications, such as nosocomial infections. Third, we did not analyze microbiologic data, so it is possible that some of the cases were being treated for confirmed bacterial infection. However, results of microbiological testing (ie, cultures of blood and sputum specimens) are generally not finalized before several days, so it is unlikely that these factored much into the clinicians' early antimicrobial management decisions. Finally, the sample size of other virus--positive patients in our population was relatively small, making it difficult to draw definite conclusions about specific patient outcomes for each virus. Although we prospectively tried to identify all patients tested with the RVP, patients with influenza may have been more likely to be included. Even if such a selection bias occurred, the effect of influenza virus positivity on antibiotic management was small, making it unlikely that such a bias impacted our conclusions significantly.

In conclusion, multiplex testing has enabled a better understanding of the burden of viruses in respiratory tract infections among adults. Influenza virus positivity is associated with shorter durations of hospitalization and leads to appropriate management decisions, including instituting antivirals and a trend toward antibiotic de-escalation. However, rapid testing for a broad array of viruses does not appear, by itself, to be useful for stewardship interventions among hospitalized adult patients, unless it can be combined with additional means of ruling out bacterial coinfections.
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